Orphan Drug Approvals — May 14, 2026

ARGENX BV received label expansion approval for EFGARTIGIMOD ALFA (VYVGART) on 2026-05-08 in the Orphan Drug stream, a bullish signal with strength 5/10 and materiality 5/10, indicating expanded access in rare diseases.

ARGENX BV received label expansion approval for EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC (VYVGART HYTRULO) on 2026-05-08 in the Orphan Drug stream, a bullish signal with strength 5/10 and materiality 5/10, supporting convenience in orphan indications.

MERUS N.V. received label expansion approval for ZENOCUTUZUMAB-ZBCO (BIZENGRI) on 2026-05-08 in the Orphan Drug stream, a bullish signal with strength 5/10 and materiality 5/10, broadening its orphan footprint.

Argenx BV's dual label expansions for VYVGART and VYVGART HYTRULO in orphan indications offer potential for increased patient reach and utilization.

Merus N.V.'s label expansion for BIZENGRI provides an opportunity to capture additional orphan market share.

Three Other approvals in the Orphan Drug stream, including two from Argenx BV and one from Merus N.V., highlight execution in rare disease expansions.

{"entity"=>"ARGENX BV", "reason"=>"Dual label expansions for VYVGART and VYVGART HYTRULO signal pipeline strength but with NOT_DISCLOSED commercial metrics", "trigger"=>"peak sales updates, exclusivity details, and near-term uptake data"}

{"entity"=>"MERUS N.V.", "reason"=>"Label expansion for BIZENGRI adds bullish orphan signal amid limited commercial disclosure", "trigger"=>"market position clarification and pricing power updates"}

{"entity"=>"VYVGART HYTRULO", "reason"=>"Subcutaneous formulation label expansion may drive convenience-driven adoption in orphan space", "trigger"=>"payer coverage decisions and patient switch data"}